SH
Shukra Pharmaceuticals Ltd (SHUKRAPHAR)
₹72.48
Mkt cap
₹2,465 Cr
P/E ratio
68.40
P/B
35.36
Div yield
0.02%
ROE
28.90%
ROCE
36.90%
EPS (TTM)
₹1.06
Book value
₹2
52W range
40–74
Sector
Healthcare
Price history
Previous close
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing [1]
NSE SHUKRAPHARBSE 524632
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−1.89% from high₹72
₹40+80.93% from low₹74
Current
₹72.48
Prev close
₹70.99
Day
+2.10%
Price performance
1D
+2.10%
1W
+21.96%
1M
+39.57%
3M
—
6M
—
1Y
—
YTD
+74.99%
Financials
Revenue, profit & margin
P/E ratio
68.4×
SHUKRAPHAR is 98% above the sector median of 34.6×
SHUKRAPHAR68.4×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 | |
| Expenses | 20 | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 2 | |
| Operating Profit | 0 | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | -0 | 27 | 1 | 21 | |
| OPM % | 1.7% | 21% | 51% | 41% | 25% | 12% | 37% | 55% | 24% | -7% | 69% | 11% | 90% | |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Profit before tax | 0 | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 20 | |
| Tax % | 2% | -0% | 1% | 24% | 41% | 39% | 23% | 29% | 26% | -1,090% | 24% | 568% | 26% | |
| Net Profit | 0 | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20 | -2 | 15 | |
| EPS in Rs | 0.01 | 0.11 | 0.22 | 0.09 | 0.01 | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.34 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Aug 202651.16%Promoter
Promoters51.16%0.21
DIIs0.11%
Public48.74%0.19
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Shukra Pharma. | ₹55.93 | 68.41 | 2,465 | 0.02% | 15 | +1,359.22% | 24 | +336.36% | 36.91% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Announcements5
AGM NOTICE 5 Sep - Shukra Pharmaceuticals AGM on 28 Sep 2026; 1% final dividend, financial statements adoption, director reappointment.Reg. 34 (1) Annual Report. 5 Sep - Shukra Pharmaceuticals schedules 33rd AGM on 28 Sep 2026; proposes 1% final dividend and director regularisation.Update On Date Of AGM 3 SepAnnouncement under Regulation 30 (LODR)-Dividend Updates 3 Sep - Record date set for final dividend of ₹0.01 per share; AGM on September 28, 2026.Board Meeting Outcome for Allottment Of Preference Shares 2 Sep - Board allotted 11,73,000 equity shares on warrant conversion for Rs.3.13 crore on 2 September 2026.